Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Bioinvent International AB
Sponsor

Bioinvent International AB

Sweden Ideongatan 1 A, 223 70 Lund, Sweden

About the sponsor

Research activity in indolent B-cell non-Hodgkin lymphoma includes relapsed and refractory disease settings, with attention to follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.

  • Rituximab-based combinations
  • Acalabrutinib
  • CD32b targeting

The sponsor’s work in this area centres on antibody-based approaches for lymphoma subtypes with limited treatment options.

About Specializations

Bioinvent International AB runs clinical trials in conditions such as Neoplasm malignant, Metastatic malignant melanoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Neoplasm malignant

Recruiting

Study of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bioinvent International AB

Neoplasm malignant

Recruiting

Study on BI-1808 and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:BI-1808
  • Sponsor:Bioinvent International AB

Metastatic malignant melanoma

Not recruiting

Study of BI-1607, Ipilimumab, and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI-1607
  • Sponsor:Bioinvent International AB

Study of BI-1206, Rituximab, and Acalabrutinib for Patients with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Bioinvent International AB

Neoplasm malignant

Not recruiting

Study on BI-1910 and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:BI-1910
  • Sponsor:Bioinvent International AB

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.